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Polymorphism in drug compounds can cause significant problems for industrial-scale production and so a 
method for restricting the conformational freedom of the target compound whilst retaining desired 
chemical properties is highly beneficial to the pharmaceutical industry. Co-crystallisation is commonly 
used to alter the structure of an active pharmaceutical ingredient (API) without affecting its activity. A 10 
comprehensive co-crystal screen of four fenamic acid derivatives affords a strictly limited number of co-
crystals. These show no evidence of polymorphism, although some of the parent APIs exhibit significant 
polymorphism. Two of these co-crystals, of mefenamic acid and tolfenamic acid with 4,4’-bipyridine, 
were previously unknown and are studied using X-ray diffraction. Co-crystals from this screen are fully 
characterised and display comparable solubility and stability with respect to the parent APIs; no phase 15 
transformations have been identified. A range of crystallisation techniques, including cooling and 
grinding methods, are shown to afford single polymorphic forms for each of the co-crystals.
Introduction 
Fenamic acid (FEN) and its derivatives are a well-known class of 
non-steroidal anti-inflammatory drugs (NSAIDs) that have been 20 
studied extensively in the solid state. Flufenamic acid (FLU), 
mefenamic acid (MEF) and tolfenamic acid (TOL) (Fig. 1), which 
are the subject of this paper, have previously been shown to exhibit 
conformational polymorphism; this is manifested particularly in 
FLU which has nine reported polymorphs.1-4 This polymorphic 25 
nature can be attributed to the torsional freedom of the amine 
functionality positioned between the two phenyl rings. The amine 
group can form an intramolecular hydrogen bond with the 
carboxylic acid group on the adjacent phenyl ring, common to all 
derivatives, which locks this half of the molecule into a planar 30 
geometry. Meanwhile the other half, a second phenyl ring, has 
torsional freedom which is influenced by the functional groups 
present.  
 
Fig. 1 Chemical structures of fenamic acid derivatives and the co-former 35 
4,4’-bipyridine 
 It is vital to understand polymorphism in materials, notably 
active pharmaceutical ingredients (APIs), as the variation in solid 
state packing can have a profound effect upon physicochemical 
properties of the solid form such as solubility and stability.5-7 There 40 
are several possible routes to obtain a desired solid form; this 
includes use of specific crystallisation techniques (such as hot melt 
extrusion8, spray drying9 and cooling crystallisation10), or through 
crystallisation with additives. The term additive encompasses both 
size-matched components and polymers that are used to influence 45 
the crystallisation process without integration into the crystal 
structure.1,4,11 Lee and co-workers have demonstrated templating 
of metastable MEF form II using FLU as an additive.12 Multi-
component materials can provide an alternative route to solid form 
control through the formation of either solvates, hydrates, salts or 50 
co-crystals.13 Similar to polymorphism, these types of compounds 
can also have improved physicochemical properties whilst 
retaining the activity of the API. Co-crystals are the focus of the 
presented work.  
 There are a limited number of known salts of fenamic acid 55 
derivatives and even fewer examples of co-crystals (multi-
component molecular crystals in which no proton transfer has 
occurred between the API and co-former, leaving both components 
neutral). Reported salts include MEF with a range of 
alkanolamines14 as well as tetraazacyclododecane, 60 
tetraazacyclotetradecane and tris(hydroxymethyl)-
aminomethane.15 Previously reported co-crystals of the fenamic 
acid series contain co-former molecules that are dominated by 
cyclic amines including nicotinamide, 4,4’-bipyridine, pyridine, 2-
aminopyridine, 4-aminopyrazine and piperazine.16-19 65 
 This study aims to discover whether co-crystallisation of 
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fenamates can afford enhanced polymorphic stability whilst 
achieving solubility and chemical stability comparable to the target 
compound. The fenamate family provides ideal target candidates 
due to the high level of polymorphism exhibited by this class of 
molecules. The different polymorphs can exhibit variation in solid 5 
form properties and so are unfavourable for their scale-up into 
optimised production processes. A thorough co-crystal screen, 
which involved co-crystallisation of the four fenamic acid 
derivatives with a wide range of second components (co-formers) 
in an array of solvents, was used to investigate the variety of co-10 
crystals accessible. This is important in order to develop a robust 
industrial crystallisation process where there is a single solid form 
product with comparable physical properties to that of the desired 
polymorph of the target API. There is no evidence in the 
Cambridge Structural Database (CSD)20 of fenamate co-crystals 15 
involving hydrogen bonding of carboxylic acid groups from 
disparate molecules. The interaction of the carboxylic acid groups 
between two fenamic acid derivatives appears to be too strong to 
be disrupted by the carboxylic acid functionality of a co-former. 
Therefore the co-formers investigated were predominantly 20 
selected as they contain basic nitrogen atoms and these have been 
shown to interact with the carboxylic acid groups of  
fenamates.14-19  
 Solubility and stability of two previously reported co-crystals of 
FLU17 and FEN19 with 4,4’-bipyridine (BP) are presented in this 25 
study along with two co-crystals of TOL and MEF with BP‡  which 
were identified during our co-crystal screening process. Solubility 
data for the starting materials are also included here, as the solvent 
systems used in this study differs from those previously 
reported.12,17 Despite 4,4’-bipyridyl being a non-GRAS (Generally 30 
Recognised as Safe) molecule, it was utilised as a very common 
co-former which lends itself to hydrogen bonding due to the 
basicity of the ring-bound nitrogen.22 
 To our knowledge the co-crystals reported herein have 
previously been produced only through evaporative or grinding 35 
methods. In the interest of scale-up and optimisation for industrial 
crystallisation, we present here the successful co-crystallisation of 
a series of fenamates with BP via cooling crystallisation. The 
optimisation of crystallisation within a cooling environment is of 
particular importance as the majority of industrial crystallisation 40 
processes are achieved through this technique23,24 either in batch 
cooling crystallisation using stirred tank reactors or continuous 
crystallisation processes. 
Experimental 
MEF, FLU, FEN and BP were purchased from Sigma Aldrich 45 
Chemie Gmbh (Steinheim, Germany) and TOL was purchased 
from TCI UK Ltd (Oxford, UK). All reagents were used without 
further purification. Laboratory grade solvents purchased from 
Sigma Aldrich were used for all crystallisations.  
 50 
Evaporative crystallisation  
Thorough co-crystal screening studies were conducted through 
                                                 
 
‡ While the present manuscript was in its first stage of revision, Surov et 
al. in parallel synthesised and determined the X-ray crystal structures of 
TOL-BP and MEF-BP co-crystals.21 
evaporative crystallisation methods using several different GRAS 
co-former molecules, solvents, ratios of API:co-former and 
crystallisation temperatures (ca. 300 crystallisations, variables 55 
detailed in Table S1†). Powder X-ray diffraction was initially used 
to screen all samples for the presence of new co-crystals. This led 
to the identification of two initially unknown‡ co-crystals which 
were structurally characterised using single crystal X-ray 
diffraction after single crystals of suitable quality were obtained 60 
through evaporative crystallisation methods; the previously 
reported structure of FLU-BP was also re-determined. The 
following evaporative conditions were used to produce the four co-
crystals characterised in this investigation: 
FEN-BP. Pale brown crystals were obtained by dissolving ca. 65 
equimolar quantities of FEN (26 mg, 0.12 mmol) and BP (20 mg, 
0.12 mmol) in a minimal volume of ethanol. The solution was left 
to evaporate at room temperature. 
FLU-BP. Bright yellow needle-like crystals were obtained within 
24 hours after dissolving ca. equimolar quantities of FLU (30 mg, 70 
0.12 mmol) and BP (17 mg, 0.11 mmol) in a minimal volume of 
methanol and leaving the solvent to evaporate at room temperature.  
MEF-BP. Equimolar quantities of MEF (30 mg, 0.12 mmol) and 
BP (20 mg, 0.12 mmol) were placed into a vial and dissolved in a 
minimal volume of isopropanol (IPA). Holes were pierced in the 75 
lid to allow for slow evaporation at 4 °C. After two days single 
crystals (pale yellow blocks) were present in solution.  
TOL-BP. Equimolar quantities of TOL (30 mg, 0.11 mmol) and 
BP (18 mg, 0.11 mmol) were dissolved in a minimal volume of 
acetone. The solution was left at room temperature to evaporate 80 
slowly and yellow needle-like crystals were observed after 24 
hours.  
 
Liquid-assisted grinding   
All samples used for the solubility and stability measurements 85 
were prepared by kneading a 2:1 molar ratio of the API to BP with 
a pestle and mortar for 15 minutes with drop-wise addition of 
ethanol and IPA for the FEN-BP and MEF-BP co-crystals, 
respectively, and methanol for the FLU-BP and TOL-BP co-
crystals. Powder X-ray diffraction (PXRD) was used to confirm 90 
that the solid forms of the kneaded samples were the same as those 
obtained from the slow evaporation method (see Fig. S1†). 
Cooling crystallisation 
All co-crystals resulting from the evaporative screens were also 
produced using two different cooling procedures; a rapid cooling 95 
method and a controlled linear cooling route detailed below. The 
quantities of the co-crystal components were initially based on the 
solubility data obtained for the individual APIs in an IPA/H2O 
solvent system. Although this method was successful for FEN-BP, 
this proved unsuccessful for FLU-BP producing a physical mixture 100 
of the individual components and very low yields of the MEF-BP 
and TOL-BP co-crystals. The molar ratios were therefore adjusted 
until the desired co-crystals could be produced reproducibly. 
Furthermore, in order to maximise the yield obtained for MEF-BP 
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and TOL-BP the solvent system was changed to IPA and ethanol 
respectively.   
Rapid cooling  
FEN-BP. Equimolar quantities of FEN (35 mg, 0.16 mmol) and 
BP (26 mg, 0.17mmol) were dissolved in 5 g of IPA/H2O (1:1 v/v) 5 
in a 10 ml glass vial, to produce a solution saturated with respect 
to FEN. Once dissolved the solution was rapidly cooled in an ice 
bath to yield pale brown crystalline needles.  
FLU-BP. A solution of FLU (50 mg, 0.18 mmol) and BP (14 mg, 
0.09 mmol) was prepared using 5 g of IPA/H2O (1:1 v/v) to give a 10 
2:1 (FLU:BP) solution saturated with respect to FLU. After 
dissolution the solution was rapidly cooled in an ice bath which 
produced bright yellow crystalline needles.  
MEF-BP. Equimolar quantities of MEF (75 mg, 0.31 mmol) and 
BP (49 mg, 0.31 mmol) were dissolved in 5 g of IPA in a 10 ml 15 
glass vial, to produce a solution saturated with respect to MEF. 
Subsequently the solution was rapidly cooled in an ice bath to 
produce a pale yellow polycrystalline powder. 
TOL-BP. TOL (150 mg, 0.57 mmol) and BP (60 mg, 0.38 mmol) 
were dissolved in 5 g of ethanol in a 10 ml glass vial, to give a 20 
solution saturated with respect to TOL in a 3:2 molar ratio 
(TOL:BP). This solution was rapidly cooled in an ice bath to give 
a pale yellow polycrystalline powder. 
 
Controlled linear cooling  25 
The components were placed in 10 ml vials to which 5 g of solvent 
was added. The chosen solvent and respective masses of the 
starting materials used were the same as for the rapid cooling 
experiments. These vials were subjected to a linear cooling profile 
of 50 °C to 5 °C at 0.05 °C min-1 using the Cambridge Reactor 30 
Design Polar Bear Plus crystalliser. Magnetic bottom stirring was 
used to obtain a stirring rate of 300 rpm.  
 
Single crystal X-ray diffraction. X-ray diffraction data were 
recorded on an Agilent Technologies Gemini A Ultra CCD 35 
diffractometer, using monochromatic Mo-K radiation 
(λ = 0.71073 Å) at 150 K.  The sample temperature was controlled 
using an Oxford Diffraction Cryojet apparatus and the data 
processed using CrysAlisPro version 1.171.36.21. The structures 
were solved by direct methods using SHELXS-97 and full matrix 40 
least-squares refinement was carried out using SHELXL-97.25 All 
non-hydrogen atoms were refined anisotropically and the 
hydrogen atoms were placed based on the Fourier difference maps. 
Molecular parameters for all structures were computed using the 
program PLATON.26 Crystallographic data and refinement 45 
parameters confirmed the known structures of all complexes, 
including the very recently reported MEF-BP and TOL-BP (Table 
S2†).21   
 
Powder X-ray diffraction. PXRD patterns were collected in flat 50 
plate mode on a Bruker D8 Advance equipped with 
monochromated Cu-Kα radiation (λ = 1.54056 Å) in reflection 
geometry at 298 K. 
 
Thermal analysis. Differential scanning calorimetry (DSC) 55 
studies were carried out using a Thermal Advantage Q20 DSC 
from TA Instruments, equipped with Thermal Advantage Cooling 
System 90 and operated with a dry nitrogen purge gas at a flow rate 
of 18 cm3 min-1. The samples were placed in sealed Tzero 
aluminium pans and a heating/cooling rate of 10 K min-1 was used. 60 
Data were collected using the software Advantage for Qseries.27 
Complementary visual characterisation of the thermal properties of 
the co-crystals was carried out using a Mettler Toledo FP82 hot 
stage equipped with a Leica DM1000 microscope. Each crystal 
was subjected to a programmed temperature regime using the FP90 65 
Central Processor. The crystals were filmed using an Infinity 2 
microscopy camera. 
 
Relative humidity studies. Samples of the BP co-crystals, 
prepared by liquid-assisted grinding, and their corresponding 70 
fenamic acid starting materials were stored under moderate (24 °C 
and 45% relative humidity) and harsh (45 °C and 80% relative 
humidity) humidity conditions for a four and two week period 
respectively. Samples were taken at regular intervals and analysed 
using PXRD to determine the stability of the materials under these 75 
conditions with time. 
 
Infrared spectroscopy. The FTIR spectra were recorded at room 
temperature using a Perkin Elmer FTIR Spectrometer in the range 
4000-500 cm-1 with an ATR sampling accessory. 80 
 
Solubility measurements. Solubility studies were carried out in a 
mixed solvent system of IPA and water (1:1 v/v) using a 
CrystallinePV parallel crystalliser from Technobis Crystallization 
Systems BV (formerly Avantium Pharmatech BV). Comprised of 85 
eight individually controlled reactors each with a working volume 
of 3-8 cm3, the CrystallinePV couples turbidity measurements with 
in-line particle visualisation and was used to obtain the necessary 
solubility information. The combination of turbidimetric data and 
images from in-line cameras allows determination of clear points 90 
with improved accuracy over turbidity measurements alone. Vials 
were cycled through temperature ranges from 20 °C to 75 °C using 
a heating rate of 0.5 K min-1 and stirring at 800 rpm using standard 
(4 mm) magnetic stirrer bars. Data were analysed using 
CrystalClear software.28 It should be noted that this solvent system 95 
is generally regarded as acceptable for deployment in 
crystallisation processes within the pharmaceutical industry. 
Results and Discussions 
Solid-state structures 
The two recently reported co-crystals, also initially discovered in 100 
parallel in this study (MEF-BP and TOL-BP) as well as the 
previously reported complexes FEN-BP and FLU-BP can be 
prepared through evaporative methods, cooling methods and by 
liquid-assisted grinding. A range of other GRAS co-formers were 
explored; however no new pharmaceutically relevant  105 
co-crystals were prepared. The scarcity of co-crystals of fenamic 
acid derivatives, as reported in this study and in previous literature, 
is due to both the strong carboxylic acid homodimer synthon that 
is dominant within the numerous polymorphs of the fenamic acid 
derivatives, and the ability for the molecules to adopt several stable 110 
conformations of their own. The strength of these interactions 
within these systems results in the evident preferential formation 
of polymorphs over co-crystals. Observations on the structures and
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Fig. 2 Experimental PXRD patterns of the co-crystals from rapid and controlled cooling crystallisation experiments and comparison with their calculated 
patterns 
intermolecular interactions of these systems are given in the ESI,  
the most significant being: 5 
 2:1 API:BP complexes of all the co-crystals contain the 
common acid-pyridine hydrogen bonded heterosynthon 
and intramolecular N-H···O hydrogen bond (Fig. S2, 
Table S3†). 
 the conformations of the molecules differ (Fig. S3 and 10 
S4†), and are affected by hydrogen bonding and - 
stacking– these conformational preferences can have an 
effect on reducing the polymorphic propensity of the 
complexes. 
 The co-crystalline products of FLU-BP, MEF-BP and TOL-BP 15 
prepared through the evaporative crystallisation method were 
analysed using PXRD for comparison with patterns calculated 
from the respective single crystal X-ray diffraction data (Fig. S1†). 
The peak positions and peak intensities of the experimental 
patterns match those of the computed patterns thus indicating that 20 
the single crystal used for structure determination is representative 
of the bulk material and contained no excess starting material.  
Cooling Crystallisation 
All samples obtained from the rapid cooling and controlled cooling 
crystallisations were analysed using PXRD (Fig. 2) and show that 25 
all four co-crystals can be reproducibly prepared on this scale. 
Interestingly, both the rapid cooling profile and the controlled 
cooling profile (0.05 °C min-1) give the same crystalline form 
which may be an indication of the favourability and stability of 
these fenamate BP co-crystals.    30 
 
Thermal analysis 
A heat-cool cycle was carried out using DSC for each of the co-
crystals and their corresponding APIs (Figs 3 and 4). Hot-stage 
microscopy (HSM) was also used to visualise the thermal event of 35 
melting for the co-crystals and to observe any other obvious phase 
changes upon heating or cooling (Fig. 5). 
 The DSC trace of FEN shows a single endothermic peak at 
186 °C upon heating and two exothermic peaks at 116 and 106 °C 
upon cooling. FLU also displays one endothermic peak at 135 °C 40 
which corresponds to the melting point of the most stable 
polymorphic form of flufenamic acid. Both FEN and FLU 
decompose upon heating and thus the recrystallisation peaks seen 
for FEN could be assigned to decomposition products. The 
co-crystals of FEN and FLU with BP melt at lower temperatures 45 
(146 and 128 °C) than their free acids and recrystallise upon 
cooling at 116 and 107 °C respectively (Fig. 3).  
 The DSC trace of MEF shows an endothermic peak at 170 °C 
which corresponds to an enantiotropic phase transition of form I to 
form II.2, 29, 30 This is followed by another endothermic peak at 50 
231 °C which represents the melting point of MEF form II. Upon 
cooling an exothermic peak is observed at 135 °C which could be 
attributed to the recrystallisation of form I, which is stable at lower 
temperatures.2 The DSC traces for TOL form I and form II both 
show a sharp endotherm at 213 °C which agrees with previously 55 
reported results.4 Upon cooling, an exothermic peak is observed at 
135 °C for form I and 150 °C for form II.   
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Fig. 3 Heat-cool DSC traces of a) FEN, b) FEN-BP, c) FLU and d) FLU-
BP 
Fig. 4 Heat-cool DSC traces of a) MEF (the y-component has been 
multiplied by three to clearly show the phase transition at 170 °C), b) 5 
MEF-BP, c) TOL Form I, d) TOL Form II and e) TOL-BP 
 The DSC profiles of MEF-BP and TOL-BP display endothermic 
peaks at 163 and 156 °C upon heating and exothermic 
recrystallisation peaks at 151 and 98 °C upon cooling (Fig. 4). In 
contrast to the DSC profile for FEN-BP and FLU-BP, where it can 10 
convincingly be stated that the co-crystals recrystallise upon 
cooling (owing to similar enthalpy changes for the endotherm and 
exotherm); the asymmetric and smaller exotherms for the other two 
co-crystals suggests a more complex thermal event than a simple 
recrystallisation of the co-crystal. These results are consistent with 15 
the events observed in the HSM images whereby the 
recrystallisation process is clearly evident upon cooling for the 
FEN and FLU co-crystals but not for the MEF-BP and TOL-BP 
samples (Fig. 5).  
 20 
Fig. 5 HSM images illustrating the crystal morphologies of the BP co-
crystals and their melts. a) FEN-BP and b) FLU-BP show evidence of 
recrystallisation upon cooling while c) MEF-BP and d) TOL-BP do not. 
 As many of the polymorphs of the fenamic acid derivatives 
differ only in a slight conformational change they have very similar 25 
melting points; the MEF form I to form II enantiotropic transition 
is an exception to this statement. It is common for phase transitions 
to be seen in DSC traces of polymorphic pharmaceuticals and it is 
therefore significant that in the DSC traces of these co-crystals 
there are no additional endothermic or exothermic peaks prior to 30 
melting that can be associated with a typical phase transition.  
 Furthermore, no polymorphs of the co-crystals were observed 
during the extensive co-crystal screen; this suggests locking of the 
conformational freedom on formation of the co-crystal structures 
has resulted in a reduction in the propensity for polymorphism in 35 
these fenamic acid derivatives. 
 The melting points of all of the co-crystals are significantly 
lower than those of their corresponding API, with the largest 
difference of ca. 66 °C between the melting point of the MEF-BP 
co-crystal and that of polymorphic form II of MEF (Table S4†). 40 
IR spectra 
Fourier Transform infrared spectroscopy was used to study the 
conformational and structural changes of the important functional 
groups involved in the hydrogen bonds. In the free acids, the 
carboxylic acid groups form standard R2
2(8) dimers (Fig. 6 a). In 45 
contrast, the co-crystals contain pyridine-acid supramolecular 
synthons and thus the carbonyl groups are not directly involved in 
the intermolecular hydrogen bonds and instead form a stronger 
intramolecular hydrogen bond with the secondary amine of the 
fenamic acids (Fig. 6 b). 50 
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Fig. 6 Hydrogen bonding synthons present in a) pure fenamates and b) 
co-crystals  
Detailed FTIR studies have been conducted on MEF form I and 
form II. It has been shown that form I, which contains the 
intramolecular hydrogen bond has an N-H stretching mode that 5 
occurs at a lower frequency (3311-3312 cm-1) than form II (3346-
3347 cm-1) in which the intramolecular hydrogen bond no longer 
exists.31 In all our results we see a redshift for the N-H stretching 
mode upon co-crystal formation indicating a strengthening of the 
intramolecular hydrogen bond. The C=O stretching mode 10 
undergoes a blueshift upon co-crystal formation, which is further 
supported by a decrease in the carbonyl bond length (Table 1). The 
dimeric hydrogen-bonded units that are commonly seen for the 
stable polymorphs of the fenamic acid derivatives have carbonyl 
stretching modes that occur at marginally lower frequencies than 15 
the co-crystals due to the increased C=O bond length which is due 
to a slight pull from the hydrogen bond acceptor. The large shifts 
(between 10 and 53 cm-1) observed for the relevant stretching 
modes within these systems confirms the formation of co-crystals 
(Fig. S5†). 20 
Table 1 Vibrational frequencies and bond lengths of selected functional 
groups partaking in hydrogen bonding for both the free fenamic acid 
derivatives and new co-crystals 
Vibration frequency 
(cm-1) 
FEN FEN-BP FLU FLU-BP 
N-H stretch 3334 3286 3320 3293 
C=O stretch 1653 1666 1651 1671 
C=O bond length (Å) 1.233 1.214 1.234 1.220 
Vibration frequency 
(cm-1) 
MEF MEF-BP TOL (I)/(II) TOL-BP 
N-H stretch 3308 3285 3339/3322 3286 
C=O stretch 1647 1670 1654/1659 1664 
C=O bond length (Å) 1.232 1.219 1.234/1.241 1.221 
Relative humidity studies 
A number of APIs are known to interconvert between polymorphic 25 
forms as well as anhydrous and monohydrate forms under 
relatively mild humidity conditions. This can cause serious issues 
with production, storage and transport of pharmaceutical products, 
and it has been shown that co-crystal formation of APIs can reduce 
or eliminate the possibility of these undesirable transformations.32-30 
35 The co-crystals of the fenamic acid derivatives studied here, 
along with the API starting materials, were thus investigated under  
Fig. 7 PXRD patterns from the FEN-BP humidity study conducted at  
80 % RH and 45 °C 
moderate humidity storage conditions (24 °C and 45 % RH) and 35 
‘stress’ humidity storage conditions (45 °C and 80 % RH) over a 
period of four and two weeks, respectively. PXRD patterns were 
recorded at various intervals and remained unchanged showing no 
indication of either new products being formed (possible hydrates) 
or dissociation of the co-crystals into their individual components 40 
(Fig. 7, Fig. S6† and Fig. S7†). These types of transformations 
normally occur at the higher humidity conditions (>75 % RH) and 
have been found to be dependent on the aqueous solubility of the 
two components.35, 36 The fenamic acid derivatives investigated 
herein, however, are not known to form hydrates and have a low 45 
aqueous solubility thus the likelihood of the co-crystals 
dissociating at higher humidity conditions is low. 
Solubility measurements 
The solubilities of all four co-crystals and their corresponding API 
starting materials have been determined and compared. When 50 
evaluating the solubility of the raw starting materials, FLU is found 
to be more soluble than the other fenamic acid derivatives (5 mg g-1 
at 25 °C) while MEF and TOL have very low solubilities in the 
IPA and water solvent system used. The new co-crystals of each 
fenamic acid derivative also follow this trend with the FLU-BP 55 
complex possessing the highest solubility.  
Figure 8 shows the determined solubilities for each of the four 
target materials, and the comparison with that for their 
corresponding BP co-crystal. These results show that the solubility 
of the co-crystals is comparable to that of the parent APIs. It is 60 
important to note that these values only take into account the mass 
of the API within the co-crystal, allowing direct comparison with 
the solubility of the pure API.  
 Upon rapid cooling of a saturated solution of TOL, yellow 
needles of TOL form II were produced in sufficient quantity to 65 
allow the solubility of this polymorphic form to be determined in 
addition to that of TOL form I. 
Conclusions 
This work reports the co-crystal screening of a series of fenamic 
acid derivatives. A total of four co-crystals were discovered from 70 
these screens, two of which have been previously known and two 
discovered in parallel in this work and in a recent report.21 These 
four co-crystals of fenamic acid, flufenamic acid, mefenamic acid 
and tolfenamic acid with the co-former 4,4’-bipyridine have been  
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Fig. 8 Solubility curves for the APIs and co-crystals in isopropanol: water 
(1:1 v/v) 
crystallised reproducibly here by a range of methods and 
characterised in terms of their thermal behaviour along with the 
determination of their key physical properties. The determination 5 
of these solid-form molecular structures and their physicochemical 
analysis add to the library of previously reported co-crystals 
discovered en route to enhancing important solid-state properties, 
such as thermal stability and solubility, of these NSAIDs.   
 In the pharmaceutical industry it is vitally important for APIs to 10 
display long term solid form stability. This is of particular note for 
polymorphic APIs, such as the fenamate family studied here, 
where phase transitions can occur due to heat and pressure 
changes, especially during secondary processing. It has been 
shown in this study that co-crystallisation enables these 15 
polymorphic transformations to be minimised, which is illustrated 
through the thermal investigations on four of the fenamic acid 
derivatives and their respective co-crystals. DSC measurements 
demonstrated that while the melting points of the co-crystals were 
lowered with respect to the APIs, the four fenamate co-crystals 20 
displayed no evidence of thermally induced phase transitions in 
contrast to the parent APIs. Although the APIs in this study are co-
crystallised with the non-GRAS co-former 4,4’-bipyridine, it 
serves as a proof of concept model for future investigations into 
inhibition of polymorphism in APIs as solid form stability and 25 
selectivity has been achieved under the experimental conditions 
investigated here.   
 The stability of the reported co-crystals provides a robustness 
with respect to the crystallisation method used for their production. 
A variety of crystallisation methods, including rapid and controlled 30 
cooling, evaporative and grinding crystallisations, have all 
produced the desired co-crystals, in a single polymorphic form and 
reproducibly. This is of the utmost importance for large-scale 
production where available techniques and environmental control 
can be variable.  35 
 It is of particular value that co-crystallisation has been achieved 
through cooling methods as this is the most commonly used 
technique in industrial crystallisation at present. Additionally, co-
crystallisation  through liquid-assisted grinding, which has been 
demonstrated in this investigation, can be translated to a screw 40 
extrusion process on an industrial scale.37 This offers 
environmental benefits through a significant or complete reduction 
in solvent use38 and thus minimises the risk of potentially toxic 
residual solvent remaining in the end product.39,40  
 Turbidimetric measurements have provided solubility data of 45 
the APIs and their 4,4’-bipyridine co-crystals over a temperature 
range of 25-70 °C in an IPA/water solvent system. Characterising 
the solubility of starting materials and products is an early step in 
designing any cooling crystallisation process and is fundamental to 
the optimisation of scale-up to industrial crystallisation volumes. 50 
The data presented will be beneficial to the design and optimisation 
of future cooling crystallisation processes comprising these 
materials. 
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